http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210052709-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0e9bca1120ab9d2f65b138f53e3eda4d |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-521 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57423 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-686 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate | 2019-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80b3429042e5cabff3227aabc48d6fd7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03a0676b44282b4a85dc174620b070e2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2cae587d0ade36f6061e3cc56dceaa3b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a62aa77ddcdde0f4f15f96c965cddef5 |
| publicationDate | 2021-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20210052709-A |
| titleOfInvention | CXCL13 marker predictive of responsiveness to immunotherapy in a patient with lung cancer and use thereof |
| abstract | The present invention relates to a biomarker for predicting responsiveness to immunotherapy of lung cancer patients and its use, and more specifically, comprising a CXCL13 gene or a protein encoded by the gene, a marker composition for predicting immunotherapy responsiveness of lung adenocarcinoma patients, immunity It relates to a composition for predicting treatment responsiveness, and a method of providing information for predicting immunotherapy responsiveness, and it was confirmed that CXCL13 was significantly upregulated in patients administered an immune checkpoint inhibitor using the composition according to the present invention. Through the CXCL13 gene or the protein encoded by the gene can be usefully used in related research fields as a predictive marker for anticancer treatment reactivity against lung cancer, and the development of an enhancer that enhances the level of the mRNA of the CXCL13 gene or the protein encoded by the gene Through this, it is expected that it can be used as an immunotherapy adjuvant that enhances the anticancer treatment effect of lung cancer. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023158093-A1 |
| priorityDate | 2019-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 238.